Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Article in English | IMSEAR | ID: sea-150447

ABSTRACT

Background: Though benign breast diseases are very common with nearly 1/3 of women suffering some time during their life time, not many studies have focused on this entity, especially in rural areas. Our teaching hospital situated amongst the villages in rural part of India provided the right background for the study. Objective: To determine the frequency of benign breast diseases in a teaching hospital situated in the rural setting and to analyze the role of triple assessment in assessing benign breast diseases. Study design: Prospective, descriptive study. Setting: MVJ Medical College and Research Hospital, Hoskote, Bangalore Rural district, Karnataka, India. Method of study: Data including age, complaints, clinical examination, radiological investigations and histopathological diagnosis was collected from patients presenting to the department of surgery with breast complaints. Patients with carcinoma of the breast were excluded from the study. Results: A total of 110 patients were studied between November 2009 to March 2011. Mean age of patients was 28.6 years. Fibroadenoma was the most common diagnosis in 56.4% followed by fibroadenosis in 20.9%. There was one case each of lipoma, tuberculosis and duct ectasia and two cases of atypical ductal hyperplasia. The sensitivity of clinical diagnosis in our study was 91.1% and FNAC was 100% accurate in all patients with fibroadenoma but had a sensitivity of only 78% in the diagnosis of fibroadenosis. Only 3.3% of cases of fibroadenoma were treated conservatively.

2.
Indian J Lepr ; 1998 Oct-Dec; 70(4): 369-88
Article in English | IMSEAR | ID: sea-55571

ABSTRACT

This report provides results from a controlled, double blind, randomized, prophylactic leprosy vaccine trial conducted in South India. Four vaccines, viz BCG, BCG+ killed M. leprae, M.w and ICRC were studied in this trial in comparison with normal saline placebo. From about 3,00,000 people, 2,16,000 were found eligible for vaccination and among them, 1,71,400 volunteered to participate in the study. Intake for the study was completed in two and a half years from January 1991. There was no instance of serious toxicity or side effects subsequent to vaccination for which premature decoding was required. All the vaccine candidates were safe for human use. Decoding was done after the completion of the second resurvey in December 1998. Results for vaccine efficacy are based on examination of more than 70% of the original "vaccinated" cohort population, in both the first and the second resurveys. It was possible to assess the overall protective efficacy of the candidate vaccines against leprosy as such. Observed incidence rates were not sufficiently high to ascertain the protective efficacy of the candidate vaccines against progressive and serious forms of leprosy. BCG+ killed M. leprae provided 64% protection (CI 50.4-73.9), ICRC provided 65.5% protection (CI 48.0-77.0), M.w gave 25.7% protection (CI 1.9-43.8) and BCG gave 34.1% protection (CI 13.5-49.8). Protection observed with the ICRC vaccine and the combination vaccine (BCG+ killed M. leprae) meets the requirement of public health utility and these vaccines deserve further consideration for their ultimate applicability in leprosy prevention.


Subject(s)
Adolescent , Adult , Aged , BCG Vaccine , Child , Child, Preschool , Double-Blind Method , Drug Evaluation , Female , Humans , India , Infant , Leprosy/prevention & control , Male , Middle Aged , Mycobacterium leprae , Vaccines, Inactivated
3.
Indian J Lepr ; 1998 Jul-Sep; 70(3): 277-86
Article in English | IMSEAR | ID: sea-54300

ABSTRACT

BCG is one of the vaccines used, as control arm, in an ongoing large scale comparative leprosy vaccine trial in South India. The objective of the present study was to examine, in the local population, the sensitizing ability, as measured by skin test reactions to tuberculin, and reactogenecity, in terms of skin lesions at the site of vaccination, for the two batches of BCG vaccine used in the above trial. The study was undertaken in 816 tuberculin-negative, previously not vaccinated school children, aged five to 14 years. Each child received one of the two batches of BCG vaccine or normal saline (control), by random allocation. At 12 weeks from vaccination, character and size of local response, at the vaccination site, were recorded. At the same time, the children were retested with tuberculin and post-vaccination reactions to the test were measured after 72 hours. At three years after vaccination all available children were re-examined for the presence and size of BCG scar at the site of vaccination. It was found that healing of vaccination lesions was uneventful, with both batches of BCG. The mean size of the lesion was similar for the two batches, the overall mean being 6.3 mm. The mean size of post-vaccination tuberculin sensitivity increased with age, and it was 14.5 mm and 15.6 mm. The sensitizing effect attributable to the vaccine was 11 mm and 12 mm, for the two batches of BCG respectively. This study showed that the two batches of BCG, in a dose of 0.1 mg, used in the ongoing leprosy vaccine trial were acceptable in terms of vaccination lesion and were highly satisfactory in terms of development of hypersensitivity.


Subject(s)
Adolescent , BCG Vaccine/administration & dosage , Child , Child, Preschool , Cicatrix , Humans , India , Leprosy/prevention & control , Skin Tests , Tuberculin/immunology
4.
Indian J Lepr ; 1998 ; 70 Suppl(): 47S-61S
Article in English | IMSEAR | ID: sea-55205

ABSTRACT

This study was undertaken to find out the deformity profile, utilization of disability care services, factors associated with underutilization and the impact of educating leprosy patients with visible disabilities in self-care practices in the area covered by the LCU Chittoor. The disability prevalence rate in the area was 15 per 10,000 population. Training of the staff and teaching leprosy patients in self-care practices has shown a remarkable improvement in skin texture and ulcer situation of disabled leprosy patients.


Subject(s)
Adolescent , Adult , Aged , Child , Child, Preschool , Disabled Persons , Female , Health Services/statistics & numerical data , Humans , India , Infant , Infant, Newborn , Leprosy/complications , Male , Middle Aged
5.
Indian J Lepr ; 1996 Oct-Dec; 68(4): 315-24
Article in English | IMSEAR | ID: sea-55317

ABSTRACT

M.w vaccine is one of the antileprosy vaccines under test in an ongoing comparative vaccine trial in South India. The objective of the present study was to examine the sensitizing ability, as measured by skin test reactions to Rees' MLSA and lepromin, and reactogenicity of M.w vaccine in the local population. Two doses of M.w, 1 x 10(9) bacilli and 5 x 10(9) bacilli, were used, in two separate studies of 395 and 400 "healthy" individuals aged 1-65 years. In each study, the study subjects received either M.w vaccine or normal saline (control), by random allocation. The results showed that healing of vaccination lesions was uneventful although the healing process was somewhat prolonged with the higher dose. The mean size of lesions was 7.0 mm and 9.5 mm with the low and high doses of the vaccine, respectively. The results also showed that M.w vaccine in a dose of 1 x 10(9) bacilli, failed to induce post-vaccination sensitization as measured by reactions to Rees' MLSA and by Fernandez and Mitsuda reactions to lepromin-A. However, when the dose of the vaccine was increased to 5 x 10(9) bacilli the mean sizes of post-vaccination reactions to Rees' MLSA and lepromin-A (both early and late) were significantly larger in the vaccine group compared to that in the control group. The sensitizing effect attributable to the vaccine was of the order of 1.5 mm to 1.8 mm.


Subject(s)
Adolescent , Adult , Aged , Bacterial Vaccines/administration & dosage , Child , Child, Preschool , Dose-Response Relationship, Immunologic , Follow-Up Studies , Humans , Immunization , Infant , Lepromin/immunology , Leprosy/immunology , Middle Aged , Nontuberculous Mycobacteria/immunology , Mycobacterium bovis/immunology , Mycobacterium leprae/immunology , Skin Tests , Vaccination
6.
Indian J Lepr ; 1996 Apr-Jun; 68(2): 167-74
Article in English | IMSEAR | ID: sea-54521

ABSTRACT

ICRC vaccine is one of the candidate anti-leprosy vaccines under test in a large scale comparative vaccine in trial. The objectives of the present study was to study the sensitization potential, as measured by Rees' MLSA and lepromin, and reactogenicity of this vaccine preparation in the local population. The study included 368 'healthy' individuals aged 1-70 years. Each individual received either ICRC vaccine or normal saline (control) by random allocation. They were also tested with Rees' MLSA and lepromin-A, 12 weeks after vaccination. Reactions to Rees' MLSA were measured after 48 hours and those to lepromin-A after 48 hours and three weeks. Character and size of local response, at the vaccination site, were recorded at 3rd, 8th and 15th week after vaccination. The results of the study showed that healing of vaccination lesion was uneventful, the mean size of the lesion being 10.3 mm. The mean sizes of post-vaccination reactions, to Rees' MLSA and lepromin (both early and late reactions), were significantly higher in the vaccine group compared to that in the normal saline group; the sensitizing effect attributable to the vaccine was of the order of 3.5 mm, 1.7 mm and 2.2 mm respectively. In conclusion, the study has demonstrated that ICRC vaccine was 'safe' and produced significant sensitizing effect as measured by post-vaccination sensitization to Rees' MLSA and lepromin, in the local population.


Subject(s)
Adolescent , Adult , Aged , Analysis of Variance , Antigens, Bacterial/diagnosis , Bacterial Vaccines/immunology , Child , Child, Preschool , Double-Blind Method , Female , Humans , Infant , Lepromin/diagnosis , Leprostatic Agents/immunology , Leprosy/prevention & control , Male , Middle Aged , Skin Tests , Statistics, Nonparametric , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL